Table 2.

In vitro susceptibility of Enterobacterales collected in six Latin American countries^a divided into two 3-year time periods 2015‒2017 and 2018‒2020.

Collection years (n)	Compound	Range	MIC50	MIC90	CLSI Interpretationb
		(µg/mL)			%S	%I	%R
2015‒2017 (7736)	Amikacin	≤0.25 – >32	2	8	96.5	1.6	1.8
	Aztreonam	≤0.015 – >128	0.12	128	69.2	1.9	28.9
	Cefepime	≤0.12 – >16	≤0.12	>16	71.0	5.5	23.4
	Ceftazidime	≤0.015 – >128	0.25	64	70.9	3.3	25.9
	Ceftazidime-avibactam	≤0.015 – >128	0.12	0.5	99.3	NA	0.7
	Colistin	≤0.06 – >8	0.25	>8	NA	83.0	17.0
	Imipenem	≤0.03 – >8	0.25	2	84.6	7.5	7.8
	Levofloxacin	≤0.004 – >8	0.25	>8	61.1	5.5	33.4
	Meropenem	≤0.004 – >8	0.03	0.12	94.6	0.8	4.6
	Piperacillin Tazobactam	≤0.25 – >128	4	128	77.9	4.3	17.8
2018‒2020 (7479)	Amikacin	≤0.25 – >64	2	8	94.8	2.3	2.9
	Aztreonam	≤0.015 – >128	0.12	>64	63.6	2.7	33.7
	Cefepime	≤0.12 – >32	≤0.12	>32	64.5	7.7	27.7
	Ceftazidime	≤0.015 – >128	0.5	>64	64.5	3.7	31.8
	Ceftazidime-avibactam	≤0.015 – >128	0.12	1	97.2	NA	2.8
	Colistin	≤0.06 – >8	0.5	>8	NA	80.2	19.8
	Imipenem	≤0.06 – >8	0.25	4	80.1	6.6	13.3
	Levofloxacin	≤0.25 – >8	0.5	>8	58.8	6.6	34.5
	Meropenem	≤0.06 – >16	≤0.06	1	90.4	1.0	8.6
	Piperacillin Tazobactam	≤0.12 – >64	2	>64	73.8	5.5	20.7

^aCountries included Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela.

^bS, susceptible; I, intermediate; R, resistant.